Robert F. Friel, chairman and chief executive officer, PerkinElmer, said, “The acquisition of Caliper Life Sciences brings innovative molecular imaging and detection technologies to our portfolio, complementing our world-leading offerings in life science, diagnostics, environmental, and food markets. The R&D, application expertise, and intellectual property of the combined organization will provide our customers with enhanced knowledge and services and a strong pipeline of innovation. Additionally, the proven leadership and talent of the Caliper team will be a strong addition to our organization.”
The combined technology platforms will expand PerkinElmer’s wide range of solutions and services for global customers including (1) broader offerings for molecular, cellular, animal, and tissue imaging to enable translational medicine research; (2) addition of a world-leading microfluidics platform for genomics and proteomics applications, for improved detection and screening through low sample use and efficiency; (3) high-value sample preparation technologies for key scientific workflow areas such as next-generation DNA sequencing; (4) more comprehensive solutions and services for identification of therapeutic response, biotherapeutics development, and biologics quality assurance/quality control (QA/QC); (5) platform technology additions to fuel expansion into attractive areas such as detection for environmental contaminants and food pathogens; and (6) broadening services capabilities, leveraging multivendor asset management, custom research, and profiling for contaminants and adverse effects.
Kevin Hrusovsky, chief executive officer, Caliper Life Sciences, noted, “We are delighted to become part of PerkinElmer. For 10 years, Caliper has partnered with strategic customers to develop a compelling suite of discovery technologies for broad life science applications. I am excited by both PerkinElmer’s ability to leverage its global reach for the delivery of solutions and the opportunity to accelerate the development of important advances that make a difference in improving human and environmental health. I am confident this is the correct strategic direction at this time for Caliper customers, shareholders and employees, and we are looking forward to becoming part of one of the leading companies in our industry.”
Mr. Hrusovsky is anticipated to join the PerkinElmer senior leadership team following the close of the transaction. The acquisition has received the unanimous support of the Boards of Directors of both companies, and it is expected to close in the fourth quarter of 2011.
Caliper Life Sciences is a provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper Life Sciences is developing new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper Life Sciences’ range of products includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions.
PerkinElmer, a global leader focused on improving the health and safety of people and the environment, reported revenue of approximately $1.7 billion in 2010. The company has approximately 6,200 employees serving customers in more than 150 countries.
Related Links:
PerkinElmer
Caliper Life Sciences
